Oracle leads a concentrated pharmacovigilance software market

By AI, Created 5:09 PM UTC, May 18, 2026, /AGP/ – Oracle held the largest share of the global pharmacovigilance and drug safety software market in 2024, according to The Business Research Company. The report says the sector is fairly concentrated, with rising demand for automated safety monitoring, signal detection and regulatory-compliant data tools shaping competition.

Why it matters: - The pharmacovigilance and drug safety software market is central to drug safety monitoring, regulatory reporting and compliance. - Strong demand for automated adverse event reporting and safety signal detection is pushing vendors toward more integrated platforms. - Market concentration suggests high entry barriers for new software providers.

What happened: - Oracle Corporation led global sales in 2024 with a 4% market share. - The Business Research Company published its Pharmacovigilance and Drug Safety Software Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report identifies Oracle, ArisGlobal, Accenture, IQVIA, IBM, Deloitte, Capgemini, Cognizant, Wipro and Genpact as the top 10 players by revenue share.

The details: - The top 10 players accounted for 32% of total market revenue in 2024. - Oracle’s life sciences and safety software division offers adverse event reporting systems, drug safety database management platforms, regulatory compliance solutions and risk monitoring tools. - Other major companies in the market include Parexel, Ennov Group, PharmaLex, EXTEDO, Anju Software, Indegene, RXLogix, AB Cube, Sarjen Systems and Clinevo Technologies. - Major raw material suppliers listed in the report include SAP, SAS Institute, Veeva Systems, Honeywell International, ClinChoice, Revvity, Tata Consultancy Services, Infosys, Tech Mahindra and Saama Technologies. - Major wholesalers and distributors listed in the report include McKesson, Cardinal Health, Cencora, Owens & Minor, Medline, Henry Schein, Movianto, Uniphar, Phoenix Pharmahandel, Zuellig Pharma, Sinopharm and Shanghai Pharma. - Major end users listed in the report include Novartis, Pfizer, Roche, Johnson & Johnson, Sanofi, GSK, AstraZeneca, Merck, Bristol Myers Squibb, AbbVie, Eli Lilly, Bayer, Boehringer Ingelheim, Amgen, Gilead, Takeda, Biogen and CSL. - The report says the market is shaped by stringent drug safety reporting regulations, global pharmacovigilance guidelines and the complexity of adverse event data management. - The report highlights unified adverse event platforms as a key trend, with benefits including consolidated safety data, better signal detection and faster regulatory decisions. - In March 2026, the U.S. Food and Drug Administration launched a centralized adverse event monitoring system across drugs, biologics, vaccines, cosmetics and animal products. - The FDA system includes real-time data publishing, advanced analytics and enhanced APIs for reporting and analysis. - The report links current company strategy to drug safety compliance, safety signal detection, modern adverse event reporting systems and AI-driven automation. - The report also provides a free sample request and a full report link: Request a free sample and Access the full report.

Between the lines: - A 32% share for the top 10 vendors shows a market that is competitive but not fragmented. - The emphasis on compliance, data reliability and analytics indicates that product depth and regulatory expertise matter as much as software features. - The FDA’s centralized reporting platform could accelerate expectations for similar workflow integration across the industry.

What’s next: - The report expects strategic collaborations, product innovation and regional expansion to strengthen leading vendors. - Vendors are likely to keep investing in automation, analytics and regulatory-compliant data management as safety reporting requirements grow. - Market competition is likely to stay tied to how well platforms reduce reporting friction and improve signal detection.

The bottom line: - Oracle leads a concentrated market where regulatory capability, automation and integrated safety data tools are becoming the main competitive edge.